Immune response analysis from ex vivo tissues from patients treated with immune checkpoint molecules
December 2017
National Cancer Center, Tokyo, Japan
Immune checkpoint molecules have durable clinical benefits in various types of cancers. Yet the clinical response is heterogeneous and highlights the need to identify biomarkers to better predict the response. In this study, the researchers explored comprehensive immune cell responses associated with clinical benefits using peripheral blood from patients with malignant melanoma treated with anti-PD-1 monoclonal antibodies. Pre- and post-treatment samples were collected and subjected to mass cytometry assays that measured the expression levels of proteins linked to immune responses. The study shows an increase of a subset of immune cells which can be used as a predictor of clinical response to PD-1 blockade therapy in patients with malignant melanoma.
Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma
Hiroyoshi Nishikawa
Added on: 07-29-2021
[1] https://academic.oup.com/intimm/article/30/1/13/4774075[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
